Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

89Bio Inc (NQ: ETNB )

11.76 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 11.76
Bid (Size) 11.60 (2)
Ask (Size) 12.50 (5)
Prev. Close 11.76
Today's Range 11.76 - 11.76
52wk Range 2.000 - 15.50
Shares Outstanding 52,230,621
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Charles Schwab To Rally Over 19%? Here Are 10 Other Analyst Forecasts For Monday
HC Wainwright & Co. cut the price target for 89bio, Inc. (NASDAQ: ETNB) from $27 to $25. HC Wainwright & Co. analyst Ed Arce maintained a Buy rating. 89bio shares fell 5.2% to trade at $11.80 on... 
Via Benzinga
Analyst Ratings for 89bio
 
Via Benzinga

Performance

YTD
-1.75%
-1.75%
1 Month
-15.33%
-15.33%
3 Month
+19.27%
+19.27%
6 Month
+106.68%
+106.68%
1 Year
+207.85%
+207.85%

More News

Read More
89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From 89bio, Inc.
Via Globe NewsWire
89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology
From 89bio, Inc.
Via Globe NewsWire
7 Analysts Have This to Say About 89bio
Via Benzinga
DraftKings To Rally Around 38%? Here Are 10 Other Analyst Forecasts For Tuesday
Via Benzinga
89bio to Present Additional Pegozafermin Data in Severe Hypertriglyceridemia from Phase 2 ENTRIGUE Study at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology
From 89bio, Inc.
Via Globe NewsWire
89bio to Participate in the SVB Securities Global Biopharma Conference
From 89bio, Inc.
Via Globe NewsWire
89bio Provides Business Update and Outlook for 2023
From 89bio, Inc.
Via Globe NewsWire
20 Favorite Biotech & Medical Stocks For 2023
Via Talk Markets
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
US Stocks Slightly Lower; Nasdaq Down 100 Points
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
89bio Announces Publication of Results of Phase 1b/2a Study of Pegozafermin for the Treatment of NASH in The Lancet Gastroenterology & Hepatology
From 89bio, Inc.
Via Globe NewsWire
89bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From 89bio, Inc.
Via Globe NewsWire
89bio Presents Additional Exploratory Analyses from the Phase 1b/2a NASH Study of Pegozafermin at AASLD The Liver Meeting® 2022
From 89bio, Inc.
Via Globe NewsWire
ServiceNow, Teladoc Health And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Via Benzinga
$9 Million Bet On 89bio? 3 Stocks Insiders Are Buying
Via Benzinga
AVEO Pharmaceuticals, Akouos And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Via Benzinga
89bio to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference
From 89bio, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Analyst Ratings for 89bio
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
Via Benzinga
Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.